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Summary 
The T  cell receptor (TCR) recognizes a ligand composed of a major histocompatibility com- 
plex (MHC) molecule and a peptide antigen. Prior studies of murine T  cell clones have dem- 
onstrated that residues in the CDR3 region of TCR interact with amino acids in the peptide 
during MHC-restricted antigen recognition. However, the questions of whether direct TCR- 
MHC contacts are made and where such contact sites might map in the TCR have not been 
resolved. In this study, we have taken advantage of the promiscuous recognition of a peptide 
from influenza virus (HA 307-319) by human T  cell clones to map sites in the TCR that me- 
diate differences in human leukocyte antigen-D related (HLA-DR) restriction in the presence 
of a common peptide antigen. Site-specifc mutagenesis of cloned TCR genes and transfection 
into Jurkat cells were used to demonstrate that single amino acid substitutions in CDR2  of the 
TCR-ci chain controlled whether a T  cell was restricted by the product of a single DR allele 
(DR7) or would respond to the HA 307-319 peptide when presented by the products of one 
of several different DR alleles  (DR1, DR4, DR5, or DR7). Because the relevant DR alleles 
are defined by polymorphism in the DR-[3 chain, these results also suggest a rotational orienta- 
tion for recognition in which TCR-o~ interacts with DR [3. 
T 
he human TCR for antigen plays a crucial role in con- 
ferring specificity on T  cell responses through its inter- 
action with the complex ligand formed by peptide antigens 
and  HLA  molecules.  Functionally,  this  is  accomplished 
through  the  combination  of genomic  rearrangement  of 
germline gene segments and somatic diversification mecha- 
nisms to generate the range ofspecificities necessary to rec- 
ognize a diverse set of  potential ligands.  However, the mo- 
lecular structure of TCRs thus formed and the identities of 
TCR residues  required for ligand recognition remain largely 
unresolved.  Fine-resolution mapping  of the  crystal struc- 
ture  of isolated  TCR  molecules,  in  conjunction with  in 
vitro mutagenesis studies to identify functionally important 
TCR residues, should help to clarify the nature of the tri- 
molecular complex formed by TCR, HLA, and antigen. 
TCR  molecules and the genes that  encode them have 
significant primary sequence homology with Igs. Given this 
strong homology between TCR and Ig,  a reasonable ap- 
proximation of TCR structure might be obtained by mod- 
eling TCR on an F~b fragment (1-3). Using this approach, 
Davis and Bjorkman (2) proposed a model of the trimolec- 
ular complex in which TCR interacts with MHC and pep- 
tide in a specific stereotypic manner. In this model, CDRs 
1 and 2 of the TCR contact the cl-helical portions of  MHC 
whereas  CDR3  interacts  with  peptide.  Such  a  model  is 
consistent with the general requirement that a given indi- 
vidual  in  the  population  needs  to  be  able  to  mount  re- 
sponses to a diverse set ofpeptide antigens in the context of 
only a limited set of  MHC alleles. This is most simply done 
by proposing that the  highly diverse CDR3  region plays 
the major role in recognition ofpeptide antigens. 
General support for this type of model has  come from 
studies in several systems where mutations introduced into 
CDR3 of the TCR have been shown to specifically affect 
peptide antigen recognition (4, 5). Jorgensen et al. (6) dem- 
onstrated  that  a  moth  cytochrome c  peptide  (MCC  88- 
103) 1, when substituted at putative TCR contact positions, 
selected T  cells bearing receptors with compensating muta- 
tions in CDR3 from mice transgenic for one chain of an 
MCC  88-103--specific TCR.  These results  clearly suggest 
an important role for CDR3  residues in peptide recogni- 
tion.  However,  attempts  to  transfer  antigen  specificity 
through CDR3 mutagenesis or grafting have had only mixed 
success,  and  additional  interactions  seem  to  be  required. 
For example, Katayama et al. (3) demonstrated that antigen 
specificity could be transferred between TCRs by grafting 
CDR3[3  regions,  but  that  restoration of full antigen-spe- 
~Abbreviations used in this paper: B-LCL, B lymphoblastoid  cell line; DR, 
D related; HA, hemagglutinin; MCC, moth cytochrome  c; PMA, phor- 
bol myristate acetate. 
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as well.  Hong et al.  (7) attempted to identify additional in- 
teractions  beyond  those  in  CDR3  by  creating  chimeric 
TCRs through the exchange of the amino-terminal portion 
of the Vexs between two T  cell clones. Whereas CDR3 se- 
quences in this system could be shown to play an important 
role  in  antigen  specificity  (for  a  conalbumin  peptide), 
MHC  fine  specificity  was  altered  by  the  exchanging  of 
CDR1  and  CDR2  in  the  chimeric  Vet  chain  constructs. 
Other  studies  have  reported  loss  of antigen-specific  re- 
sponses in T  cell clones upon mutation  of CDR1  and/or 
CDR2 residues  (8-11). Finally, Ehrich et al.  (12) observed 
that single amino acid substitutions  in either the CDR3  of 
TCR  or in the peptide  at putative  T  cell contact residues 
could also affect the  recognition  of MHC  molecules with 
substitutions  at  distant  sites.  These  results  suggest  that,  at 
least  in  some  systems,  peptide-CDR3  interactions  may 
dominate but are not the exclusive determinants  of the re- 
sponse.  Far  less  is  known  about  direct  contacts  between 
TCR  and MHC because of the ditficulty in isolating them 
from TCR-peptide interactions. 
To  dissect  the  molecular  recognition  of HLA-peptide 
complexes by human TCRs and to define specifically resi- 
dues of TCRs that may interact with HLA, we have cho- 
sen  to  study the  D  related  (DR)-restricted  recognition  of 
the immunodominant peptide of influenza virus hemagglu- 
tinin,  HA 307-319.  TCR  genes isolated from HA-specific 
T  cell clones were altered by in vitro mutagenesis and then 
reintroduced into appropriate  recipient T  cell lines to assess 
their function. Recognition of the HA 307-319 peptide by 
human  T  cells  represents  an  ideal  system  to  investigate 
direct interactions between residues in TCRs and antigen- 
presenting  molecules,  because  the  peptide  binds  degener- 
ately to an assortment  of different allelic  HLA-DR  mole- 
cules,  including  DR1,  DR2,  DR4w4,  DR5,  and  DR7 
(13). Amino acid substitution studies of the peptide suggest 
that it binds different DR molecules in a relatively standard 
conformation  and  have  identified  potential  TCR  contact 
sites  in  the  peptide  (14).  X-ray crystallographic  studies  of 
the HA 307-319 peptide complexed to DR1 are consistent 
with  the  results from amino acid substitution  studies  (15). 
Studies  of TCRs  recognizing  a  conserved  peptide  in  a 
common conformation presented  by different  DR  mole- 
cules permit  the  separate  identification  of specific  contact 
sites  for HLA and peptide  on TCR  molecules. Using this 
system,  we  demonstrate  here  that  T  cell promiscuity,  the 
ability of a given T  cell clone to recognize the HA peptide 
in  the  context  of different  HLA-restricting  elements,  in- 
volves interactions with residues in CDR2. 
Materials and Methods 
Cells.  T  cell clonesJS515.11 and 3BC6.6 were the generous 
gifts ofJ.  Krieger and A.  Sette  (Cytel Corporation,  San Diego, 
CA). JS515.11  recognizes the 307-319 peptide of influenza  virus 
(A/PR/8/34)  HA,  PKYVKQNTLKLAT,  presented  by  the 
products of the DRA*0101 and DRBI*0701 genes  (14). 3BC6.6 
is specific for the HA 307-319 peptide in the context of DR4w4 
(16). J.RT3-T3.5 cells, a subline of  Jurkat cells lacking cell surface 
TCR expression  owing to a defect in endogenous TCR-[3 pro- 
duction  (17),  were  obtained from the  American Type Culture 
Collection (Rockville,  MD). B lymphoblastoid  cell lines (B-LCLs) 
homozygous  for  HLA-DR  alleles, HOM-2  (DR1),  MGAR 
(DR2), CAT (DR3), Priess  (DR4w4),  Sweig (DRS),  and DBB 
(DR7), were used as APCs. Cells were cultured in RPMI 1640 
plus  10% FBS supplemented  with  glutamine,  sodium pyruvate, 
penicillin,  and streptomycin. 
TCR Usage.  RNA was prepared from T  cell  clones  by the 
method of Chomczynski and Sacchi (18). First-strand  cDNA was 
used as a template for PCR amplification  with panels of subfam- 
ily-specific 5' primers and constant region 3' primers essentially as 
described (19). Full-length copies  of expressed  TCR genes were 
obtained by PCR using primers  specified  from the appropriate 
published nucleotide sequences,  cloned into Bluescript,  and their 
nucleotide sequences were determined. The TCR genes were ex- 
cised from Bluescript,  gel-purified,  and cloned into episomal  ex- 
pression vectors (Invitrogen, San Diego, CA). TCRA genes were 
always cloned into pREP9 and TCRB genes into pREP8. 
Mutagenesis.  Chimeric  TCRA  constructs  were  created  by 
PCR with primers corresponding to regions in common between 
the parental  TCR genes. The 3' primer was used to create an ar- 
tificial PstI site by silent mutation at codon 87, thus allowing the 
exchange  of fragments  between  different  TCRs.  Site-specific 
mutations to alter residues in CDR2 c~ were generated by PCR 
with mutagenic oligonucleotides as described  (20). 
Electroporation.  Equal amounts (20  p~g) of expression  vectors 
containing TCRA and TCRB genes were introduced into J.RT3 
cells by electroporation at 250 V, 960 IxF with a Gene Pulser ap- 
paratus  (Bio-Rad, Hercules, CA). Cells were cultured in RPMI 
1640 plus 10% FBS for 3 d and then were selected in media con- 
taining 600 Ixg/ml active Geneticin (GIBCO BRL, Gaithersburg, 
MD)  and  0.5  mM  histidinol  (Sigma  Chemical  Co.,  St.  Louis, 
MO). After 2-3 wk of growth, drug-resistant  lines were stained 
with an antibody to V~3  ([3V3a; T  Cell Diagnostics,  Hercules, 
CA) and analyzed on a FACSort  |  flow cytometer (Becton Dick- 
inson, San Jose, CA). Cells were used for stimulations  within 48 h 
of staining for TCR expression. 
A.  TCRA Sequences 
CDRI  CDR2 
JS  QSVTQLGS}{VSVSEGALVLLRCNYSSSVPPYLFWYVQYPNQGLQLLLKYTTGATLVI(GIN 
3BC  ..................................................  SA ........ 
CDR3 
JS  GFEAEFKKSETSFHLTKPSAHMSDAAEYFCAVSEGGGSEKLVFGKGTKLTVNPY 
3BC  ..................................  DTSYD.VI..P..S.S.I.N 
B.  TCRB Sequences 
CDR1  CDR2 
JS  DVKVTQSSRYLVKRTGEKVFLECVQDMDHENMFWYRQDPGLGLRLIYFSYDVEMKEKGDI 
3BC  ............................................................ 
CDR3 
JS  PEGYSVSREKKERFSLILESASTNQTSMYLCASSPGTSGTTYEQYFGPGTRLTVT 
3BC  ..................................  LT..  GYT..S  ...... V 
Figure 1.  Amino acid sequences of TCRs expressed by T cell clones 
3BC6.6 andJS515.11. The names of the T cell clones are abbreviated as 
l  S (JS515.11) and 3BC (3BC6.6). Single-letter amino acid symbols are 
used. A period indicates a position of identity between the two sequences 
compared. CDRs are indicated by over- and underlining and are posi- 
tioned as described by Chothia and Lesk (1). TCRA sequences (/t) and 
TCRB sequences (B) are aligned separately. 
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and APCs (5  ￿  104) were  cultured in the presence  of various 
concentrations ofpeptide from 0 to 50 Ixg/ml; with an anti-CD3 
mAb; or with phorbol myristate  acetate  (PMA) plus  ionomycin 
in triplicate  microtiter wells in volumes of 150 p,1. IL-2 secretion 
was measured by assaying proliferation of the IL-2--dependent T 
cell line HT-2 by [3H]thymidine incorporation. Culture superna- 
tants  from T  cell stimulations  were harvested after 20-24 h and 
applied  to  HT-2  cells in  96-well  plates. After 24  h,  1 p,  Ci  of 
[3H]thymidine  (5  Ci/mmol)  was  added.  Cells  were  harvested 
16 h  later,  and  [3H]thymidine  incorporation  was  measured  by 
scintillation  counting. 
Results 
Transfected T  Ceil Receptor  Genes Reconstitute Receptor Spec- 
ificity in an Immortalized Human T  Cell Line.  Two  different 
human  T  cell  clones  specific  for  the  influenza  virus  HA 
peptide, HA 307-319, in the context of different HLA class 
II  alleles,  were  analyzed  for  their  TCR  usage.  Clone 
JS515.11  recognizes HA 307-319 in the  context of DR7, 
whereas  clone  3BC6.6  recognizes the  peptide  when  pre- 
sented  by DR4w4.  PCR  amplification  of cDNA  with  a 
panel  of oligonucleotide  primers  corresponding  to  each 
known human TCR  BV and AV subfamily and appropri- 
ate constant region primers was used to identify the unique 
V  genes expressed by each T  cell clone. PCR products in- 
dicative  of expression  were  obtained  from  each  of the 
clones  with  primers  corresponding  to  the  BV3  and  AV1 
subfamilies.  Full-length  copies  of these  expressed  AV and 
BV genes were cloned, and their nucleotide sequences were 
determined (Fig. 1). Each of the T  cell clones rearranged and 
expressed the same BV3S1 gene segment, but their 13 chains 
differed  in  the  somatically  generated  CDR3  sequences. 
The clones rearranged different alleles  of an AV1 subfamily 
member that differed by two residues,  both located in CDR2. 
The CDR3 regions of the c~ chains were also distinct. 
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Figure 2.  Expression  of  exogenous TCR in trans- 
fected cell lines. Cell-surface expression of trans- 
fected V[33 was analyzed by flow cytometry after 
staining with the primary antibody ~V3a (T Cell 
Diagnostics). A 
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Figure 3.  Specificities  of TCR transfectants 
expressing wild-type or hybrid TCRs. The se- 
cretion of IL-2 by transfected T  cells was as- 
sayed by the incorporation of tritiated thymi- 
dine by the  IL-2-dependent cell line HT-2. 
Responses to HA 307-319 presented by DR4 
(￿9  or DR7 (,) are plotted for four different 
transfected lines, expressing the TCR of clone 
3BC6.6 (,4), the TCR of clone JS515.11 (B), 
and two hybrid receptors (C-D). The structures 
of the TCR constructs  are illustrated  at left. Se- 
quences derived from the  TCR  from clone 
3BC6.6 are indicated  by open boxes. Sequences 
derived from the TCR from clone  JS5 I5.11 are 
indicated by  shaded boxes. Numbers within 
boxes indicate the  approximate locations of 
CDRs. Control values for stimulation of each 
of the constructs with an anti-CD3 mAb were 
as follows: (.4) 1.35 X 1@ (B) 1.53 X 10~; (C) 
1.24 X 10s; and (D) 1.23 ￿  10  s. 
Full-length TCRA  and TCRB  genes from the  two  T 
cell  clones were  transferred into  the  episomal  expression 
vectors pREP9 and pREP8 and electroporated into J.RT3.3 
cells.  After 2-3  wk  of selection, separate lines transfected 
with the TCR genes from JS515.11 and from 3BC6.6 each 
stained with mAbs to V[33  (Fig. 2). The TCR  transfectants 
were  challenged with HA  307-319  peptide presented by 
the DR4w4 B-LCL Priess and the DR7 B-LCL DBB (Fig. 
3, A  and B). Lines transfected with the TCR  from 3BC6.6 
responded to  the  HA peptide in a  dosage-dependent and 
HLA-restricted manner; that is, a response was only detect- 
able  when  the  peptide  was  presented  by  DR4w4,  not 
DR7. Transfectants expressing the TCR from JS515.11 re- 
sponded to  the  HA peptide when presented by DR7,  as 
expected. However, at higher peptide concentrations, there 
was  also  a  reproducible  response  to  HA  307-319  when 
presented  by  DR4w4.  To  ensure  that  the  endogenous 
TCRA  gene from J.RT3.3  cells was not involved in this 
promiscuous recognition, transfected lines were generated 
with only the  TCRB  genes ofJS515.11  and 3BC6.6 and 
assayed  for  response  to  the  HA  peptide.  Although  these 
transfected  lines  could  be  stimulated  with  an  anti-CD3 
mAb, no responses were observed with peptide at concen- 
trations up to  50  ~g/ml (data not shown), indicating that 
2046  Modulation of T Cell Receptor Recognition by Mutagenesis the endogenous  TCRA  gene  could not mediate recogni- 
tion of the HA 307-319  peptide when paired with  either 
of the exogenous TCRB  genes used in this study. 
Generation of Hybrid TCRs.  With the exception of two 
adjacent residues in CDR2  of the TCRA  chain, all of the 
primary amino acid sequence differences in the TCR.s from 
the JS515.11  and 3BC6.6 T  cell clones occur in the CDR3 
regions  (see  Fig.  1).  Since  the  TCRs  recognize the  same 
peptide, a function likely to be strongly influenced by the 
CDR3  region, hybrid receptors were  generated to  deter- 
mine whether it was possible to  "uncouple"  HLA restric- 
tion  from  the recognition  of peptide. J.RT3.3  cells were 
electroporated  with  expression  vectors  containing  the 
TCRA  gene from one  T  cell clone and the TCRB  gene 
from the other. The resulting transfectants were assayed for 
cell-surface expression of V[~3 and then stimulated with the 
HA 307-319  peptide presented by DR4w4  and by DR7 
APCs.  Despite  comparable levels of cell-surface V[33  ex- 
pression in transfected cells expressing hybrid as compared 
with  normal  receptors  and  comparable  responses  to  anti- 
CD3  stimulation, no response was  detected from cells ex- 
pressing either hybrid receptor at peptide concentrations up 
to 50 I~g/ml (Fig. 3,  C  and D). 
Generation of Chimeric Receptor Molecules.  The lack of an- 
tigen-specific responses observed in T  cell transfectants ex- 
pressing hybrid receptors indicated that the correct pairing 
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Figure 4.  Specificities  of TCR transfectants ex- 
pressing chimeric TCRs. The secretion of IL-2 by 
transfected T cells was assayed  by the incorporation 
of [3H]thymidine by the IL-2-dependent  cell line 
HT-2.  Responses to  HA  307-319  presented  by 
DR4 (￿9  or DR7 (m) are plotted for four different 
transfected  lines expressing  either a chimeric Vet in- 
corporating  CDRs  1  and  2  from  3BC6.6  and 
CDR3 fromJS515.11 in conjunction with different 
V~s  (A and  B)  or a chimeric  Vet  incorporating 
CDRs  1 and 2 from JS515.11 and  CDR3  from 
3BC6.6 in conjunction with different VI3s (C and 
D). The structures of the TCR constmcts are illus- 
trated  at leR. Sequences derived from  the  TCR 
from clone 3BC6.6 are indicated by open boxes. 
Sequences  derived  from  the  TCR  from  clone 
JS515.11 are indicated by shaded boxes. Numbers 
within boxes indicate the approximate locations of 
CDRs. Control values for stimulation of  each of  the 
constructs with an anti-CD3 1-nAb were as follows: 
(A) 1.25 ￿  105; (B)  1.02 ￿  105; (C)  1.36 ￿  105; 
and (D) 1.04 X 105. 
2047  Brawtey and Concannon of cognate CDR3  regions was necessary to obtain peptide 
recognition. To separate the CDR2  differences in the Vom 
from the CDR3 differences between the two T  cell clones, 
chimeric TCRA  genes were generated in which CDRs  1 
and  2  were  derived  from  the  Vex  of one  T  cell  clone, 
whereas  CDR3  was  derived  from  the  other.  These  chi- 
meric TCRA genes were then paired both with the correct 
and  with  the  incorrect  TCRB  gene,  and  electroporated 
into J.RT3.3 cells,  and V133-expressing lines were selected. 
The resulting lines were challenged with the HA 307-319 
peptide presented by DR4w4 and by DR7  (Fig. 4).  In the 
transfected  lines  expressing  chimeric  Vots  in  conjunction 
with  their  cognate VlBs, HLA restriction  was  determined 
by the CDR3 portion of the chimeric Vols.  For example, a 
fusion  of the  CDR1  and  2  regions  of the  Vci  from  the 
DR4-restricted  T  cell clone 3BC6.6 with the CDR3r  re- 
gion from the DR7 restricted clone JS515.11, when paired 
with the VI3 from JS515.11,  only responded  to peptide  in 
the context of DR7, but not DR4  (Fig.  4  B). Transfected 
lines expressing the chimeric Vex paired with a VI3 that re- 
sulted in a mismatch of CDR3  regions were unresponsive 
to peptide  stimulation,  although one such line did show a 
slight  response  at  high  peptide  concentration  (50  btg/ml) 
(Fig.  4  D).  Interestingly,  none of the  transfected lines  ex- 
pressing chimeric receptors displayed the promiscuous rec- 
ognition  of the  HA  307-319  peptide  that  was  observed 
with transfectants expressing the wild-type JS515.11  TCR. 
All of the transfected lines responded to anti-CD3 stimula- 
tion  (Fig.  4).  FACS  analysis  did not reveal  any significant 
differences in the levels of cell-surface expression of TCRs 
in the different transfected lines (data not shown). 
TheJS515.11  TCR Can Recognize Peptide When Presented 
by Multiple Different Allelic HLA-DR Molecules.  Transfec- 
tants expressing the TCR  from JS515.11  are promiscuous, 
responding to the HA 307-319 peptide when presented by 
either DR4 or DR7. However, transfectant lines in which 
the CDRsl  and 2 of the V0~ of this TCR  are replaced with 
sequences  from the VoL of clone 3BC6.6  only respond  to 
peptide in the context of DR7.  The HA 307-319 peptide 
binds degenerately to the products of several HLA-DR  al- 
leles in addition to DR4 and DR7. Accordingly, the speci- 
ficities of the transfectant expressing the wild-type JS515.11 
TCR  and  the  transfectant  expressing  the  TCR  with  the 
chimeric o~ chain were tested on a panel ofAPCs homozy- 
gous for DR1, DR2, DR3, DR4, DR5, and DR7. DR-13 
molecules  encoded  on  each  of these  haplotypes,  except 
DR3,  are reported  to bind the HA peptide  with approxi- 
mately similar affinities. 
As shown m  Fig. 5, the transfectant expressing the JS515.11 
TCR  responds  vigorously  to  the  HA  307-319  peptide 
when presented  by DR7  but  also responds  to the peptide 
when presented  in the  context  of DR1,  DR4,  and DR5. 
No response is seen when the peptide is presented by DR2 
or DR3.  The  transfectant  line  expressing  the  chimeric  ci 
chain  (i.e.,  the  double  mutant  T5I---~$5I,  Gs2---)A  s2)  re- 
sponded  to  the  peptide  only in  the  context  of DR7,  al- 
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Figure 5.  The effect of mutations in CDR2 on the 
specificities of T cell transfectants for the HA 307-319 
peptide presented by a panel of different HLA-DR al- 
leles. The secretion of IL-2 by transfected T cells was 
assayed by the incorporation of [3H]thymidine by the 
IL-2-dependent  cell line HT-2.  Responses to  HA 
307-319 presented by DR1, DR2, DR3, DR4, DR5, 
or DR7 are plotted for four different transfected lines 
expressing the receptor from cloneJS515.11 or variants 
with single or double point mutations in the CDR2 of 
the Vc~. 
2048  Modulation ofT Cell Receptor Recognition by MutaRenesis though the response curve was shifted toward higher pep- 
tide concentrations.  However, even at 50  ~g/ml peptide, 
there was no significant response to HA 307-319 presented 
by any of the other DR alleles. 
Single Amino Acid Substitutions  in CDR2 Dramatically Re- 
duce  Promiscuity  While  Leaving  DR7  Recognition  Intact. 
The wild-type JS515.11  receptor that mediates promiscu- 
ous recognition of HA 307-319  and the receptor with the 
chimeric ix chain that is specific for DR7 differ at only two 
adjacent  amino acid positions in CDR2  (see  Fig.  1).  The 
individual roles of these two positions, Thr-51 and Gly-52, 
in mediating promiscuity of the JS515.11  ix chain were ex- 
amined by generating transfectants  expressing ix  chains  in 
which  one of the  two positions was substituted  with  the 
corresponding residue from the ci chain from the 3BC6.6 
receptor.  Both  of these  in  vitro  mutagenized  TCRs  re- 
sponded  to  the  HA  307-319  peptide  in  the  context  of 
DR7 (Fig. 5). The mutant in which Thr-51 was substituted 
with Ser showed a response to HA 307-319  presented by 
DR7  comparable to that of the wild-type JS515.11  trans- 
fectant but with substantially reduced promiscuous recog- 
nition on other DR alleles.  The second mutant, in which 
Gly-52 was substituted with Ala, showed a response to HA 
307-319  comparable to the double mutant (i.e., the previ- 
ously described chimeric receptor) with no detectable pro- 
miscuity and a shift in the response curve to higher peptide 
concentrations in the context of DR7. 
Discussion 
In this study, we have identified sites of interaction be- 
tween human T  cell receptors and HLA-DR-peptide anti- 
gen  complexes  by  assaying the  function  of cognate  and 
mutated TCRs introduced by electroporation into a recep- 
tor-negative variant of  Jurkat cells. Sensitive, dose-dependent, 
HLA-restricted responses were observed in cells transfected 
with receptors of known specificity. Thus,  this system al- 
lowed the generation and functional testing of specific mu- 
tations  in human TCRs without  resort to a  heterologous 
system. 
The  response  to  influenza  virus  HA  307-319  peptide 
was chosen for study because of the degenerate binding of 
this peptide to a number ofallelic DR molecules, including 
DR1, DR2, DR4w4, DR5, and DR7  (13).  The ability of 
this peptide  to bind to multiple DR  molecules,  in an ap- 
parently  similar  conformation,  created  an  opportunity  to 
compare TCRs recognizing the same peptide in the  con- 
text  of different restricting elements.  Mutagenesis  experi- 
ments were designed to target domains or residues involved 
predominantly  in  HLA restriction  or in  peptide  recogni- 
tion. The TCRs of the two T  cell clones chosen for study, 
JS515.11  and 3BC6.6, each use the same BV gene segment 
and allelic  AV gene segments, differing primarily in CDR3 
sequences. Previous studies in which point mutants or chi- 
meras of murine  TCRs were  generated  have largely ob- 
served loss of function, suggesting that TCR recognition is 
highly sensitive to even minor structural alterations (8-11). 
Given the strong primary sequence homology but clear dif- 
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ference  in  HLA  restriction  between  the  TCRs  studied 
here,  we  reasoned that  chimeras between  these  receptors 
might potentially be informative in that they would be ex- 
pected to retain or gain antigen responsiveness. 
There is suggestive evidence from studies of TCR usage 
and from mutagenesis  studies  (3,  6)  that  the  two  CDR3 
domains  of TCRs  interact  directly  with  peptide.  In  the 
specific case of the response to HA 307-319,  Ostrov et al. 
(21)  previously described  two  T  cell  clones  that  differed 
only  in  their  CDR3  domains  but  had  distinct  responses 
(stimulation vs. antagonism) to a single substitution at a pu- 
tative T  cell contact residue (position 313) in the HA pep- 
tide.  Here, we observed that  CDR3IX from either TCR, 
when paired with the appropriate TCR-[3 chain, was nec- 
essary and  su~cient  for correct,  HLA-restricted  recogni- 
tion  of the  HA peptide.  Thus,  the interaction of cognate 
CDR3  regions from VIx and V[3 plays a dominant role in 
determining the HLA restriction of these receptors. 
We also observed a second effect on HLA restriction that 
was mediated by residues in CDR2o~.  At low stimulatory 
peptide concentrations, the JS515.11  receptor responded to 
HA 307-319  only in  the  context  of DR7.  However,  at 
higher  peptide  concentrations,  the  TCR  also  recognized 
the  peptide  presented by DR1,  DR4,  and DR5,  but not 
that presented by DR2 or DR3. The DR2 APC used here 
is capable of activating other HA 307-319--specific T  cell 
clones  (22),  whereas  DR3  does  not  bind  the  peptide. 
Therefore,  many,  but  not  all,  HA peptide-binding  DRs 
can present to the JS515.11  receptor. This promiscuous re- 
sponse to the peptide in the  contexts of DR1,  DR4,  and 
DR5  (in  addition  to  DR7)  was  not  observed  when 
CDR2oe was replaced with the sequence from the Vix  of 
clone 3BC6.6,  even though 3BC6.6 is restricted by DR4. 
Moreover, a modest substitution at a single CDR2c~ posi- 
tion,  Gly-52  to  Ala,  completely  abrogated  promiscuity, 
while leaving DR7-restricted recognition intact. 
Given the nature  of the  amino acids involved, it seems 
unlikely that either glycine or alanine at position 52 makes 
a  direct  contact  with  the  DR  molecule.  However,  this 
leaves open  the  possibility that  such  a  substitution  might 
have a broader effect on conformation.  In some Ig mole- 
cule  structures,  glycine residues  in  CDRs  have been  ob- 
served to play an important role (23).  In such small loops, 
the  presence  and position  of glycine  residues  may define 
the conformation. Thus, the effect of the glycine-to-alanine 
substitution at position 52 may be to distort the conforma- 
tion of the loop formed by CDR2IX.  Consistent with this 
interpretation are the results of alanine substitution analyses 
of the CDRs of TCRot and TCR[3 from a routine arsonate- 
specific T  cell clone in which dramatic decreases in antigen 
responsiveness were observed (11). 
Domains of the TCR and HLA are large enough to ac- 
comodate contacts between  multiple TCR  loops and  the 
ix-helical portions of the DR molecule. Indeed, Kasibhatla 
et al (11)  observed that all six CDR regions of the murine 
T  cell clone they studied were simultaneously involved in 
recognition  of MHC-peptide  complexes.  Modeling  of a 
TCR from a pigeon cytochrome c-reactive T  cell clone sug- gests that the CDR regions in TCR, although distinct in the 
primary sequence,  are  tightly packed in the  three-dimen- 
sional structure  (3).  A  variety of systems provide evidence 
for CDR3 domain interactions with peptide antigen. How- 
ever, in some systems, V gene usage (and hence CDR1 and 
CDR2  sequences)  is  also  reported  to  be  restricted  in  re- 
sponse to a given antigen.  Chien and Davis (24)  have sug- 
gested that TCR  interactions with MHC  and peptide may 
be  fluid,  with  peptide-CDR3  contacts  dominating  but 
with other contacts involved in fine tuning the interaction. 
This model is consistent with the results of our mutagenesis 
studies, in which the CDIK3et domain, paired with its cog- 
nate  CDR3[3 domain, is necessary and sufficient to obtain 
correct,  HLA-restricted recognition of the HA peptide by 
the T  cell clones analyzed here. Additional substitutions in 
CDR2~  can increase  or decrease the specificity of the in- 
teraction with  different allelic  DR  molecules,  but  only in 
the  context  of the  specificity conferred by the  CDR3  re- 
gions present.  For example,  when  the  CDR20t  region  of 
DR4-restricted clone 3BC6.6 is substituted into the DR7- 
restricted TCR  from clone JS515.11,  it eliminates promis- 
cuity, but creates a receptor that responds to HA 307-319 
only in the context of DR7, not DR4. Thus, these substi- 
tutions in CDRe~ can modify the HLA restriction, but can- 
not  overcome  constraints  created  by  the  CDR3  interac- 
tions with peptide and DR. 
The  observation  that  varying  CD1L2e~  while  holding 
CDR3et  and  the  entire  13  chain  constant  can  alter  MHC 
restriction  suggests that CDR2ot most likely interacts with 
polymorphic residues  in  DR  that  define  the  different  al- 
leles.  In the allelic HLA-DR  molecules studied here, poly- 
morphic residues are largely confined to the first two exons 
of the  DR-13  chain.  This  suggests a  rotational  orientation 
for the  trimolecular  complex in which the  TCR-~x  chain 
interacts  with DR  13.  Two other HA 307-319-specific  T 
cell  clones,  one  restricted  by DR1  (25)  and  the  other  by 
DR5  (21),  have  been  reported  to  use  V133 but  different 
members  of the  Ve~I  subfamily than  those  observed here, 
consistent  with  a  rotational  orientation  that  provides  for 
contacts between TCR-~x and DR [3. 
From a  technical perspective,  these studies  indicate  that 
JR_T3.3 cells are an acceptable host cell line for functional 
studies of the specificity of transfected human TCR  genes, 
in that the TCR transfectants faithfully reproduce the spec- 
ificities  of the  primary  T  cell  clones.  This  approach  may 
have some utility as a molecular alternative to traditional T 
cell cloning.  Since expressed TCR  gene sequences  can be 
derived from very small numbers  of cells,  such as  those at 
the sites  of infections or autoimrnune lesions, it may be de- 
sirable to isolate and immortalize the specificities of T  cells 
that rmght be difficult to clone by cellular methods through 
a  combination  of PCR  amplification  and  transfection.  T 
cell lines constructed by these methods could then be used 
to  screen  cDNA  libraries  for  their  target  antigens  as  has 
been done for tumor antigens (26). Alternatively, it may be 
possible  to  generate  libraries  of TCR-transfected  T  cells 
that could be screened with candidate antigens. 
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